With the increased throughput of single cell platforms and sequencing of immune repertoires, new challenges arise and the ability to map individual antibodies to antigens is becoming increasingly important. What is LIBRA-seq? Mapping B cell receptor-antigen interaction at single cell level Dr. Georgiev’s group at the Vanderbilt University has developed a high-throughput, highly-multiplexed sequencing-based technique… Continue reading LIBRA-seq: accelerating antibody discovery
Month: August 2021
NGS, Sanger & PacBio sequencing in Antibody Drug Discovery
Biologics are becoming the drugs of choice when targeting cancers, infectious diseases etc. Monoclonal antibodies have taken up 6 out of 10 of the top selling drugs in the latter years and biologic drugs are expected to keep being some of the most efficient and potent drugs available. To find good drug candidates new sequencing… Continue reading NGS, Sanger & PacBio sequencing in Antibody Drug Discovery
Non-antibody scaffolds as therapeutics.
non-antibody scaffolds from ERR3474167.fastq downloaded from the European Nucleotide Archive. These non-antibody scaffolds can make great therapeutics due to their small size although there can be tradeoffs.
ISO 27001 Compliance in Life Science
PipeBio is the ISO 27001 certified bioinformatics cloud for antibody drug discovery and screening. Today we sat down with Reidar Poulsen of ProcessManager and learned about his job as an ISO consultant, what it means for a company to become ISO 27001 compliant and what the certification is all about. Here is the transcript: Great… Continue reading ISO 27001 Compliance in Life Science